Research
Cellular
No significant differences were observed in biliary cancer or hepatocellular carcinoma between GLP-1 RAs and other oral antidiabetic medications.
Clinicians can consider GLP-1 RAs without increased concern for biliary or liver cancer risks.
StrongSupportsmedium confidence
No significant differences were observed in biliary cancer or hepatocellular carcinoma.
Why this rating
Based on a large retrospective cohort study design.
Source
Gastrointestinal and Hepatobiliary Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
Chengu Niu et al. · The American Journal of Gastroenterology · 2025
DOI 10.14309/ajg.0000000000003760
cohort · n=460830Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →